创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: ADCC Platform Features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-18 15:25
  • Views:

(Summary description)With the continuous progress of science and technology, mankind's understanding of life sciences is deepening. In this process, by virtue of its excellent R&D strength and innovation ability, InnoModels Biotechnology has successfully built an ADCC (Antibody Dependent Cytotoxicity) in vitro killing experimental platform, which opens up a new path for the research and development of tumor immunotherapy.

InnoModels Biotechnology: ADCC Platform Features

(Summary description)With the continuous progress of science and technology, mankind's understanding of life sciences is deepening. In this process, by virtue of its excellent R&D strength and innovation ability, InnoModels Biotechnology has successfully built an ADCC (Antibody Dependent Cytotoxicity) in vitro killing experimental platform, which opens up a new path for the research and development of tumor immunotherapy.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-18 15:25
  • Views:
Information

With the continuous progress of science and technology, mankind's understanding of life sciences is deepening. In this process, by virtue of its excellent R&D strength and innovation ability, InnoModels Biotechnology has successfully built an ADCC (Antibody Dependent Cytotoxicity) in vitro killing experimental platform, which opens up a new path for the research and development of tumor immunotherapy.
InnoModels' ADCC platform leads the development of tumor immunotherapy field with its unique advantages. Firstly, the platform adopts humanized mouse model (HIS) and humanized tumor xenograft platform (PDX), which makes the experimental data closer to the clinical reality, and provides a more accurate and reliable basis for the development of new drugs. Secondly, by utilizing the key players of natural immune response such as NK cells, the ADCC platform is able to efficiently attack tumor cells labeled by antibodies, providing strong support for tumor immunotherapy.

 


In the field of tumor immunotherapy, InnoModels' ADCC platform not only has a wide range of application prospects, but also has high practical value. On the one hand, through the platform, researchers can conduct in-depth studies on different types of tumor cells, further revealing the mechanisms of tumor development and progression, and providing scientific basis for early diagnosis, treatment and prevention of tumors. On the other hand, the ADCC platform can also provide powerful support for the development of new drugs, helping researchers screen out drugs with efficient anti-tumor activity and provide patients with safer and more effective treatment options.
It is worth mentioning that InnoModels Biotechnology always adheres to a patient-centered approach and is committed to providing individualized medical solutions for patients. Through the ADCC platform, doctors can formulate more precise and personalized treatment plans for patients' specific conditions, improving treatment effects and reducing treatment costs, so that patients can truly benefit.
In conclusion, with its unique advantages and application value, InnoModels' ADCC platform is leading the development of the tumor immunotherapy field. In this era full of challenges and opportunities, InnoModels Biotechnology will continue to uphold the spirit of innovation and pragmatism, and make greater contributions to the cause of human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司